Ming‐Lung Yu, Chuan‐Mo Lee, Chi‐Ling Chen, Wan‐Long Chuang, Sheng‐Nan Lu, Chen‐Hua Liu, Shun‐Sheng Wu, Li‐Ying Liao, Hsing‐Tao Kuo, You‐Chen Chao, Shui‐Yi Tung, Sien‐Sing Yang, Jia‐Horng Kao, Wei‐Wen Su, Chih‐Lin Lin, Hung‐Chih Yang, Pei‐Jer Chen, Ding‐Shinn Chen, Chun‐Jen Liu, for the Taiwan Liver‐Net Consortium – 15 January 2013 – Patients dually infected with hepatitis C virus (HCV)/hepatitis B virus (HBV) have a higher risk of developing advanced liver disease or hepatocellular carcinoma compared with monoinfected patients.

Katharina Esser‐Nobis, Inés Romero‐Brey, Tom M. Ganten, Jérôme Gouttenoire, Christian Harak, Rahel Klein, Peter Schemmer, Marco Binder, Paul Schnitzler, Darius Moradpour, Ralf Bartenschlager, Stephen J. Polyak, Wolfgang Stremmel, François Penin, Christoph Eisenbach, Volker Lohmann – 15 January 2013 – Intravenous silibinin (SIL) is an approved therapeutic that has recently been applied to patients with chronic hepatitis C, successfully clearing hepatitis C virus (HCV) infection in some patients even in monotherapy.

Justin R. Henning, Christopher S. Graffeo, Adeel Rehman, Nina C. Fallon, Constantinos P. Zambirinis, Atsuo Ochi, Rocky Barilla, Mohsin Jamal, Michael Deutsch, Stephanie Greco, Melvin Ego‐Osuala, Usama Bin‐Saeed, Raghavendra S. Rao, Sana Badar, Juan P. Quesada, Devrim Acehan, George Miller – 15 January 2013 – Nonalcoholic steatohepatitis (NASH) is the most common etiology of chronic liver dysfunction in the United States and can progress to cirrhosis and liver failure. Inflammatory insult resulting from fatty infiltration of the liver is central to disease pathogenesis.

Toshiya Kamiyama, Hideki Yokoo, Jun‐Ichi Furukawa, Masaki Kurogochi, Tomoaki Togashi, Nobuaki Miura, Kazuaki Nakanishi, Hirofumi Kamachi, Tatsuhiko Kakisaka, Yosuke Tsuruga, Masato Fujiyoshi, Akinobu Taketomi, Shin‐Ichiro Nishimura, Satoru Todo – 15 January 2013 – The altered N‐glycosylation of glycoproteins has been suggested to play an important role in the behavior of malignant cells. Using glycomics technology, we attempted to determine the specific and detailed N‐glycan profile for hepatocellular carcinoma (HCC) and investigate the prognostic capabilities.

Romain Desgrippes, Fabrice Lainé, Jeff Morcet, Michèle Perrin, Ghislain Manet, Caroline Jezequel, Edouard Bardou‐Jacquet, Martine Ropert, Yves Deugnier – 15 January 2013 – An excess of visceral adipose tissue could be involved as a modulator of the penetrance of HFE hemochromatosis since fat mass is associated with overexpression of hepcidin and low transferrin saturation was found to be associated with being overweight in women.

Petia Jeliazkova, Simone Jörs, Marcel Lee, Ursula Zimber‐Strobl, Jorge Ferrer, Roland M. Schmid, Jens T. Siveke, Fabian Geisler – 12 January 2013 – Notch signaling through the Notch2 receptor is essential for normal biliary tubulogenesis during liver development. However, the signaling events downstream of Notch2 critical for this process are less well defined. Furthermore, whether Notch signaling also underlies adult hepatic cell fate decisions is largely unknown.

Kerrilynn Carney, Sameer Dhalla, Ayse Aytaman, Craig T. Tenner, Fritz Francois – 12 January 2013 – Although injection drug use (IDU) and blood transfusions prior to 1992 are well‐accepted risk factors for hepatitis C virus (HCV) infection, many studies that evaluated tattooing as a risk factor for HCV infection did not control for a history of IDU or transfusion prior to 1992.

Xin‐Long Yan, Ya‐Li Jia, Lin Chen, Quan Zeng, Jun‐Nian Zhou, Chun‐Jiang Fu, Hai‐Xu Chen, Hong‐Feng Yuan, Zhi‐Wei Li, Lei Shi, Ying‐Chen Xu, Jing‐Xue Wang, Xiao‐Mei Zhang, Li‐Juan He, Chao Zhai, Wen Yue, Xue‐Tao Pei – 12 January 2013 – Cancer‐associated mesenchymal stem cells (MSCs) play a pivotal role in modulating tumor progression. However, the interactions between liver cancer‐associated MSCs (LC‐MSCs) and hepatocellular carcinoma (HCC) remain unreported. Here, we identified the presence of MSCs in HCC tissues.

Alina Pascale, Olivier Chazouillères, Lawrence Serfaty – 12 January 2013

Christopher E. McGowan, Ali Monis, Bruce R. Bacon, Josep Mallolas, Fernando L. Goncales, Ioannis Goulis, Fred Poordad, Nezam Afdhal, Stefan Zeuzem, Teerha Piratvisuth, Patrick Marcellin, Michael W. Fried – 12 January 2013 – Chronic infection with the hepatitis C virus (HCV) is a leading cause of global morbidity and mortality. Although recent advances in antiviral therapy have led to significant improvements in treatment response rates, only a minority of infected patients are treated. Multiple barriers may impede the delivery of HCV therapy.